| The Study of CM326 in Patients With Moderate-to-severe Atopic Dermatitis (NCT05186922) | Keymed Biosciences Co.Ltd | 2022-02-17 |
| Neuropsychologic Assessments of Dupilumab-Treated Adolescent Participants With Moderate-to-Severe Atopic Dermatitis (NCT05203380) | Regeneron Pharmaceuticals | 2022-01-27 |
| A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE SUBCUTANEOUS INJECTIONS OF SHR-1819 IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (NCT05197023) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2022-01-01 |
| A Study to Evaluate the Efficacy and Safety of CBP-201 in Moderate to Severe Atopic Dermatitis in China (NCT05017480) | Connect Biopharm LLC | 2021-08-31 |
| Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis (NCT04921345) | Galderma R&D | 2021-06-24 |
| The Study of CM310 in Patients With Atopic Dermatitis (NCT04893707) | Keymed Biosciences Co.Ltd | 2021-06-07 |
| Subcutaneously CM310/Placebo in Patients With Moderate-to-Severe Atopic Dermatitis (AD) (NCT04805411) | Keymed Biosciences Co.Ltd | 2021-02-24 |
| Dose Escalation Trial of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis (AD) (NCT04893941) | Keymed Biosciences Co.Ltd | 2020-07-21 |
| A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis (NCT04444752) | Connect Biopharm LLC | 2020-07-17 |
| Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis (NCT03989206) | Galderma R&D | 2019-12-30 |
| Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis (NCT03989349) | Galderma R&D | 2019-06-30 |
| Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis (NCT03985943) | Galderma R&D | 2019-06-27 |
| Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis (NCT03054428) | Regeneron Pharmaceuticals | 2017-03-21 |
| TREATgermany: German National Clinical Registry for Patients With Moderate-to-severe Atopic Dermatitis (NCT03057860) | Technische Universität Dresden | 2016-02-01 |
| Safety and Efficacy Study of Q301 in Moderate to Severe Atopic Dermatitis Patients (NCT02426359) | Qurient Co., Ltd. | 2015-04-01 |
| Dilute Bleach Baths in Pediatric Patients With Atopic Dermatitis (NCT01286220) | University of Texas Southwestern Medical Center | 2010-12-01 |
| Standardized Time- and Score-oriented Treatment of Moderate and Severe Atopic Dermatitis (NCT00148746) | Technische Universität Dresden | 2004-05-01 |